Details

Autor(en) / Beteiligte

• Monaci, Elisabetta
• Mancini, Francesca
• Lofano, Giuseppe
• Bacconi, Marta
• Tavarini, Simona
• Sammicheli, Chiara
• Arcidiacono, Letizia
• Giraldi, Monica
• Galletti, Bruno
• Rossi Paccani, Silvia
• Torre, Antonina
• Fontana, Maria Rita
• Grandi, Guido
• de Gregorio, Ennio
• Bensi, Giuliano
• Chiarot, Emiliano
• Nuti, Sandra
• Bagnoli, Fabio
• Soldaini, Elisabetta
• Bertholet, Sylvie

Titel

MF59- and Al(OH)3-Adjuvanted Staphylococcus aureus (4C-Staph) Vaccines Induce Sustained Protective Humoral and Cellular Immune Responses, with a Critical Role for Effector CD4 T Cells at Low Antibody Titers

Ist Teil von

• Frontiers in immunology, 2015-09, Vol.6, p.439-439

Ort / Verlag

Switzerland: Frontiers Research Foundation

Erscheinungsjahr

2015

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Staphylococcus aureus (S. aureus) is an important opportunistic pathogen that may cause invasive life-threatening infections, like sepsis and pneumonia. Due to the increasing antibiotic resistance, the development of an effective vaccine against S. aureus is needed. Although a correlate of protection against staphylococcal diseases is not yet established, several findings suggest that both antibodies and CD4 T cells might contribute to optimal immunity. In this study, we show that adjuvanting a multivalent vaccine (4C-Staph) with MF59, an oil-in-water emulsion licensed in human vaccines, further potentiated antigen-specific IgG titers and CD4 T-cell responses compared to alum and conferred protection in the peritonitis model of S. aureus infection. Moreover, we showed that MF59- and alum-adjuvanted 4C-Staph vaccines induced persistent antigen-specific humoral and T-cell responses, and protected mice from infection up to 4 months after immunization. Furthermore, 4C-Staph formulated with MF59 was used to investigate which immune compartment is involved in vaccine-induced protection. Using CD4 T cell-depleted mice or B cell-deficient mice, we demonstrated that both T and B-cell responses contributed to 4C-Staph vaccine-mediated protective immunity. However, the role of CD4 T cells seemed more evident in the presence of low-antibody responses. This study provides preclinical data further supporting the use of the adjuvanted 4C-Staph vaccines against S. aureus diseases, and provides critical insights on the correlates of protective immunity necessary to combat this pathogen.